| 04th week of 2010 patent applcation highlights part 47 |
| Patent application number | Title | Published |
|---|
| 20100022529 | AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET - The present invention provides amidophenoxyindazole compounds useful in the treatment of cancer. | 2010-01-28 |
| 20100022530 | TETRAHYDROBENZOISOXAZOLE AND TETRAHYDROINDAZOLE DERIVATIVES AS MODULATORS OF THE MITOTIC MOTOR PROTEIN - Compounds of the formula (I) in which A | 2010-01-28 |
| 20100022531 | NOVEL COMPOUNDS AS P2X7 MODULATORS AND USES THEREOF - Compounds are disclosed that have a formula represented by the following (1), the compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, pain, inflammation, traumatic injury, and others. | 2010-01-28 |
| 20100022532 | USE OF A KINASE INHIBITOR FOR THE TREATMENT OF PARTICULAR RESISTANT TUMORS - The invention provides low molecular weight compounds, namely 1H-thieno[2,3-c]pyrazoles, showing a high affinity for the ATP pocket of ABL tyrosine kinase. These compounds are thus ATP-competitive tyrosine kinase inhibitors displaying a significant inhibitory potency also, and in particular, towards BCR-ABL inhibitor-resistant T315I ABL mutants. The compounds of the invention find a useful application in the treatment of BCR-ABL inhibitor-resistant ABL-mediated diseases, such as Imatinib-resistant chronic myelogenous leukemia. Moreover, the invention provides a screening method for the identification of compounds capable of binding the ATP pocket of a kinase protein, in particular of the T315I mutant ABL kinase. | 2010-01-28 |
| 20100022533 | COMPOSITIONS AND METHODS FOR INDUCING CELL DEDIFFERENTIATION - The present invention provides compounds, compositions and methods for dedifferentiating lineage committed mammalian cells into stem cells. The present invention also provides methods of inducing dedifferentiation of lineage committed mammalian cells into stem cells, which can be further differentiated into various lineage committed cells. Methods of identifying additional compounds useful for inducing dedifferentiation of lineage committed cells into stem cells are also provided. | 2010-01-28 |
| 20100022534 | 2-BENZIMIDAZOLYL-6-MORPHOLINO-4- (AZETIDINE, PYRROLIDINE, PIPERIDINE OR AZEPINE) PYRIMIDINE DERIVATIVES AS PI3K AND MTOR INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS - The invention concerns pyrimidine derivatives of Formula (I) wherein each of p, R | 2010-01-28 |
| 20100022535 | 2-Pyridyl substituted imidazoles as ALK5 and/or ALK4 Inhibitors - 2-pyridyl-substituted imidazoles which are used advantageously in the treatment of diseases mediated by ALK 5 or ALK 4 inhibitors or both. | 2010-01-28 |
| 20100022536 | Inhibitors of Cytosolic Phospholipase A2 - This invention provides chemical inhibitors of the activity of various phospholipase enzymes, particularly cytosolic phospholipase A | 2010-01-28 |
| 20100022537 | I-PHENY 1-3,4-DIHYDROPYRIMIDIN-2(1H)-ONE DERIVATIVES AND THEIR USE - This invention relates to novel heterocyclic derivatives, processes for their preparation, and their use in medicaments, especially for the treatment of chronic obstructive pulmonary diseases, acute coronary syndrome, acute myocardial infarction and heart failure development. | 2010-01-28 |
| 20100022538 | 5-FLUORO PYRIMIDINE DERIVATIVES - This present disclosure is related to the field of 5-fluoro pyrimidines and their derivatives and to the use of these compounds as fungicides. | 2010-01-28 |
| 20100022539 | Isoxazole Compounds as Histamine H3 modulators - Certain isoxazole compounds are histamine H | 2010-01-28 |
| 20100022540 | TRIAZOLE DERIVATIVES II - Novel triazole derivatives of the formula (I) in which R | 2010-01-28 |
| 20100022541 | Chemical inhibitors of bacterial heptose synthesis, methods for their preparation and biological applications of said inhibitors - The invention relates to new compounds having heptose synthesis inhibitory properties, of formula (I) or a pharmaceutically acceptable salt, or prodrug thereof, wherein A is an aryl or heterocycle, optionally substituted by one or several identical or different R such as H, C1-C10 alkyl, C1-C10 alkyl-OR | 2010-01-28 |
| 20100022542 | COMPOUNDS EXHIBITING THROMBOPOIETIN RECEPTOR AGONISM - Pharmaceutical compositions containing as an active ingredient compounds of the general formula (I), prodrugs of the same, pharmaceutically acceptable salts of both, or solvates of them and exhibiting thrombopoietin receptor agonism: | 2010-01-28 |
| 20100022543 | CYCLOALKYLIDENE AND HETEROCYCLOALKYLIDENE INHIBITOR COMPOUNDS - The present invention provides a compound of general Formula (I) having histone deacetylase (HDAC) inhibitory activity, a pharmaceutical composition comprising the compound, and a method useful to treat diseases using the compound. | 2010-01-28 |
| 20100022544 | CYCLICALLY SUBSTITUTED 3,5-DICYANO-2-THIOPYRIDINES AND USE THEREOF - The present application relates to novel 4-cycloalkyl- and 4-heterocycloalkyl-3,5-dicyano-2-thio-pyridine derivatives, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, preferably for the treatment and/or prevention of hypertension and other cardiovascular disorders. | 2010-01-28 |
| 20100022545 | Metabotropic Glutamate Receptor Isoxazole Ligands and Their Use as Potentiators - 286 - Compounds in accord with Formula I: | 2010-01-28 |
| 20100022546 | ADAMANTYL DIAMIDE DERIVATIVES AND USES OF SAME - The present invention provides adamantyl-diamide derivatives of formula (1): | 2010-01-28 |
| 20100022547 | Compounds and Methods for Treating Mammalian Gastrointestinal Parasitic Infections - One aspect of the present invention relates to compounds, and pharmaceutically acceptable salts and prodrugs thereof, that are useful as inhibitors of IMPDH. The invention also provides pharmaceutical compositions comprising the compounds of the invention which selectively inhibit parasitic IMPDH. In certain embodiments, the present invention relates to selective inhibition of | 2010-01-28 |
| 20100022548 | USE OF N-HETEROCYCLYLMETHYLBENZAMIDES IN THERAPEUTICS - The invention relates to use of compositions in therapeutics containing a compound having general formula (I): | 2010-01-28 |
| 20100022549 | ALPHA-HELIX MIMETIC WITH FUNCTIONALIZED PYRIDAZINE - The synthesis of new α-helix scaffolds mimicking i, i+3 or i+4, i+7 residues, was accomplished. The common pyridazine heterocycle originates from the easily available dimethyl pyridazine-3,6-dicarboxylate building block. These scaffolds may be thought of as synthetic counterparts of amphiphilic α-helices having a hydrophilic face along one side and a hydrophobic face along the other side of the helix. | 2010-01-28 |
| 20100022550 | TETRAHYDROCARBAZOLE DERIVATIVES USEFUL AS ANDROGEN RECEPTOR MODULATORS - The present invention provides a compound of the formula: Formula (I) or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising an effective amount of a compound of Formula (I) in combination with a suitable carrier, diluent, or excipient; and methods for treating physiological disorders, particularly frailty, osteoporosis, osteopenia, and male and female sexual dysfunction comprising administering to a patient in need thereof an effective amount of a compound of formula (I). | 2010-01-28 |
| 20100022551 | TRIMETAZIDINE FOR USE IN THE TREATMENT OF FIBROMYALGIA SYNDROME AND RELATED CONDITIONS - The present invention provides a method for treating certain rheumatic conditions such as fibromyalgia syndrome, chronic fatigue syndrome, myofascial pain syndrome, and Gulf War syndrome, among others, by administration of trimetazidine, along with related compositions and kits. | 2010-01-28 |
| 20100022552 | KMUP-1 CAPABLE OF TREATING HYPERTENSION - A method for treating a spontaneous hypertension or a cardiomyocyte hypertrophy is provided. The method comprises a step of administering to a mammal a therapeutically effective amount of a compound of 7-[2-[4-(2-chlorobenzene)piperazinyl]ethyl]-1,3-dimethyl xanthine. | 2010-01-28 |
| 20100022553 | Therapeutic Combination Comprising an Aurora Kinase Inhibitor and Imatinib - The present invention provides a therapeutic combination comprising (a) a compound 1 of formula (A) as set forth in the specification and (b) a BCR-ABL kinase inhibitor selected from the group consisting of Imatinib, Dasatinib, Nilotinib, Bosutinib and Inno-406, wherein the active ingredients are present in each case in free form or in the form of a pharmaceutically acceptable salt or any hydrate thereof. | 2010-01-28 |
| 20100022554 | PYRIDINE DERIVATIVES FOR THE TREATMENT OF METABOLIC DISORDERS RELATED TO INSULIN RESISTANCE OR HYPERGLYCEMIA - The present invention provides novel compounds represented by the general formula (I): | 2010-01-28 |
| 20100022555 | Novel Derivatives - The present invention relates to novel piperazine derivatives; to processes for their preparation; to pharmaceutical compositions containing the derivatives; and to the use of the derivatives in therapy to treat diseases for which blocking the Ca | 2010-01-28 |
| 20100022556 | Therapeutic combinations comprising a long acting dihydropyridine calcium-channel blocker and a statin - A medicament comprising (±)-1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid 2-[4-(diphenylmethyl)-1-piperazinyl]ethyl methyl ester (manidipine) or a physiologically acceptable salt and a statin or a physiologically acceptable salt. | 2010-01-28 |
| 20100022557 | RADIOPROTECTOR COMPOUNDS AND RELATED METHODS - The invention relates to radioprotectors of formula (I), processes for their preparation and their use in protecting biological materials from radiation damage. In diagnostic and therapeutic radiology, particularly in cancer radiotherapy, the radioprotectors of the present invention may be used to protect certain normal tissues or structures from radiation damage. The radioprotectors of formula (I) may also have uses in decreasing the effects of irradiation in non-medical scenarios, both civil and military. | 2010-01-28 |
| 20100022558 | TREATMENT OF INSOMNIA - The invention relates to the use of Flibanserin for the preparation of medicaments useful for the treatment of Insomnia. | 2010-01-28 |
| 20100022559 | BISOXIMES AS FUNGICIDES - The invention relates to the novel use of bisoximes, some of which are known, for controlling unwanted microorganisms, and to processes for their preparation, and also to novel bisoximes, to processes for their preparation and to their use for controlling unwanted microorganisms and insects in crop protection and in the protection of materials. | 2010-01-28 |
| 20100022560 | THIOPHENE PYRAZOLOPYRIMIDINE COMPOUNDS - The present invention relates to compounds of Formula (I), pharmaceutical compositions thereof, and the use of such compounds as corticotropin releasing factor 1 (CRF1) receptor antagonists in the treatment of psychiatric and neuroendocrine disorders, neurological diseases, and metabolic syndrome. | 2010-01-28 |
| 20100022561 | INHIBITORS OF BRUTON'S TYROSINE KINASE - Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions. | 2010-01-28 |
| 20100022562 | Use of Plant Growth Regulators to Reduce Abscisic Acid Related Plant Leaf Yellowing - The present invention describes methods for maintaining ABA-induced drought tolerance while reducing ABA-induced leaf yellowing through the combination of ABA with selected plant growth regulators. The present invention also describes a method of using selected ABA analogs to reduce water use with minimal leaf yellowing. | 2010-01-28 |
| 20100022563 | PHOSPHODIESTERASE INHIBITOR TREATMENT - Methods and compositions are disclosed for the treatment of diseases or conditions produced by or associated with low cyclic nucleotide levels. The compositions comprise phosphodiesterase inhibitors and are formulated for intranasal and pulmonary administration. | 2010-01-28 |
| 20100022564 | PURINE AND DEAZAPURINE DERIVATIVES AS PHARMACEUTICAL COMPOUNDS - The invention provides a compound of the formula (I) or salts, solvates, tautomers or N-oxides thereof, wherein T is N or CR | 2010-01-28 |
| 20100022565 | PHARMACEUTICAL COMPOSITIONS - Provided is a pharmaceutical composition comprising a calcilytic agent which, when administered orally to a subject induces a rapid and short-lasting absorption of the calcilytic agent and/or a rapid and short-lasting release of the parathyroid hormone. | 2010-01-28 |
| 20100022566 | QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF - The present invention relates to novel quinazoline derivatives with less skin irritation and an excellent action of strongly suppressing scratching behavior, and pharmaceutical compositions containing a quinazoline derivative as an active ingredient. The present invention is directed to the quinazoline derivatives represented by the general formula [1] or pharmaceutically acceptable salts thereof. In the general formula [1], R | 2010-01-28 |
| 20100022567 | Compositions containing pufa and/or uridine and methods of use thereof - This invention provides methods of enhancing brain development; increasing or enhancing intelligence; increasing or enhancing synthesis and levels of phospholipids, synapses, synaptic proteins, and synaptic membranes by a neural cell or brain cell, comprising contacting a subject or a pregnant or nursing mother thereof with a composition comprising an omega-3 fatty acid, an omega-6 fatty acid, and/or uridine, a metabolic precursor thereof, or a combination thereof. | 2010-01-28 |
| 20100022568 | ENDOTHELIN RECEPTOR ANTAGONISTS FOR EARLY STAGE IDIOPATHIC PULMONARY FIBROSIS - This present invention relates to the use of an endothelin receptor antagonist for the preparation of a medicament for the treatment of early stage idiopathic pulmonary fibrosis. | 2010-01-28 |
| 20100022569 | INHIBITORS OF TYROSINE KINASES - The present invention relates to the use of pyrimidylaminobenzamide compounds for the preparation of a drug for the treatment of diseases that respond to modulation of Ephrin receptor kinase, especially EphB4, activity, especially for the curative and/or prophylactic treatment of proliferative diseases, and to a method of treating diseases that respond to modulation of kinase activity, especially Ephrin receptor kinase activity. | 2010-01-28 |
| 20100022570 | NOVEL MICROBIOCIDES - Compounds of the formula (I) in which the substituents are as defined in claim | 2010-01-28 |
| 20100022571 | SUBSTITUTED PYRAZOLO [3,4-B]PYRIDINES AS PHOSPHODIESTERASE INHIBITORS - The present invention relates to phosphodiesterase (PDE) type IV selective inhibitors. Processes for the preparation of disclosed compounds, pharmaceutical compositions containing the disclosed compounds and their use as PDE type IV selective inhibitors are provided. Prepared compounds correspond to structure XIV. | 2010-01-28 |
| 20100022572 | NOVEL SPIRO COMPOUND AND MEDICINE COMPRISING THE SAME - It is to provide a novel compound useful for preventing and/or treating diabetes, insulin resistance, diabetes complication, obesity, dyslipidemia, hypertension, fatty liver, or metabolic syndrome. | 2010-01-28 |
| 20100022573 | INHIBITORS OF AKT ACTIVITY - The instant invention provides for substituted naphthyridine compounds that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt activity by administering the compound to a patient in need of treatment of cancer. | 2010-01-28 |
| 20100022574 | Methods to Treat Pain Using an Alpha-2 Adrenergic Agonist and an Endothelin Antagonist - The present invention relates, in general to treatment of pain comprising administering an alpha-2 adrenergic agonist and an endothelin antagonist, wherein administration of the agents acts as an analgesic and ameliorates pain in a subject. | 2010-01-28 |
| 20100022575 | OXYMATRINE COMPOSITIONS AND RELATED METHODS FOR TREATING AND PREVENTING CHRONIC INFECTIOUS DISEASES - Compositions and methods for treating chronic infectious diseases using substantially pure oxymatrine or pharmaceutically acceptable salts or esters thereof are disclosed. In one embodiment described herein, the chronic infectious disease is chronic fatigue syndrome. Further described are compositions having an anti-infective amount of substantially pure oxymatrine or pharmaceutically acceptable salts or esters thereof. | 2010-01-28 |
| 20100022576 | STABLE AND BIOAVAILABLE FORMULATIONS AND A NOVEL FORM OF DESLORATADINE - An active pharmaceutical ingredient comprising 95% of form I of desloratadine and 5% of form II of desloratadine is disclosed. Also disclosed are a process for its preparation as well as a bioavailable and stable formulation containing this active pharmaceutical ingredient for the treatment of allergic diseases like allergic rhinitis, chronic idiopathic urticaria, asthma and other similar diseases. The compositions are formulated such as to provide protection to the drug from acidic excipients. The compositions of the present invention comprise desloratadine intimately mixed with hydrogenated vegetable oil and certain other excipients including acidic excipients. | 2010-01-28 |
| 20100022577 | DRY SYRUP CONTAINING LORATADINE - Dry syrup preparations comprising loratadine as a hydrophobic medicinal drug are provided. The loratadine dry syrup preparations can be produced using a cellulose material or an argininic acid salt together with sugar. | 2010-01-28 |
| 20100022578 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS - Inhibitors of HCV replication of formula (I) | 2010-01-28 |
| 20100022579 | SUBSTITUTED TETRAHYDROQUINOLINES - Compounds of the formula (I), in which R | 2010-01-28 |
| 20100022580 | NEW 2,3,4,5-TETRAHYDRO-1H-PYRIDO[4,3-B]INDOLE COMPOUNDS AND METHODS OF USE THEREOF - This disclosure relates to new tricyclic compounds that may be used to modulate a histamine receptor in an individual. Compounds are described, including new 2,3,4,5-tetrahydro- | 2010-01-28 |
| 20100022581 | PYRROLIDINE-SUBSTITUTED AZAINDOLE COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY - The present disclosure provides compounds having affinity for the 5-HT | 2010-01-28 |
| 20100022582 | Tetrahydroisoquinoline Compound and Medicinal Use Thereof - The present invention provide a tetrahydroisoquinoline compound having a superior ACAT-inhibitory activity and/or anti-oxidation action, particularly, novel compound represented by the formula (I) (wherein each symbol is as described in the specification) and a pharmaceutically acceptable salt thereof. | 2010-01-28 |
| 20100022583 | PYRIDINYL MODULATORS OF gamma-SECRETASE - The present invention relates to compounds of Formula I as shown below, wherein the definitions of A, X, R | 2010-01-28 |
| 20100022584 | Modulation of Glutamine Synthetase Activity - Methods of screening and designing compounds as inhibitors of glutamine synthetase are provided herein. Compounds, e.g., serine protease inhibitors, and compositions comprising the same, that are useful for the treatment, prevention, and/or amelioration of bacterial infections, including | 2010-01-28 |
| 20100022585 | BETA- AND GAMMA-AMINO-ISOQUINOLINE AMIDE COMPOUNDS AND SUBSTITUTED BENZAMIDE COMPOUNDS - Disclosed are beta and gamma-amino isoquinoline amide compounds and substituted benzamide compounds. In particular, the invention provides compounds that affect the function of kinases in a cell and that are useful as therapeutic agents or with therapeutic agents. The compounds of the invention are useful in the treatment of a variety of diseases and conditions including eye diseases such as glaucoma, cardiovascular diseases, and diseases characterized by abnormal growth, such as cancers. The invention further provides compositions containing the beta or gamma-amino isoquinoline amide compounds or substituted benzamide compounds. | 2010-01-28 |
| 20100022586 | BICYCLIC HETEROARYL INHIBITORS OF PDE4 - The present invention relates to compounds and methods which may be useful as inhibitors of phosphodiesterase 4 (PD E4) for the treatment or prevention of inflammatory diseases and other diseases involving elevated levels of cytokines and proinflammatory mediators. | 2010-01-28 |
| 20100022587 | DERIVATIVES OF 2-PHENYL-3-HYDROXYQUINOLINE-4(1H)-ONE AND METHODS OF THEIR PREPARATION AND UTILIZATION - Derivatives of 2-phenyl-3-hydroxyquinoline-4(1H)-one of the general formula (II), where X represents a nitro group, amino group, and Y represents an atom of halogen, oxygen or sulphur substituted by C | 2010-01-28 |
| 20100022588 | PHARMACEUTICAL CARRIER COMPOSITION AND PHARMACEUTICAL COMPOSITION - The present invention relates to a pharmaceutical carrier composition and a pharmaceutical composition comprising said pharmaceutical carrier composition. The pharmaceutical composition comprises: (a) at least 20% (w/w) of the composition of a sugar or a sugar alcohol; (b) one or more pharmaceutically acceptable excipients; (c) one or more pharmaceutically active ingredients in their base form; and (d) water up to 100% (w/w). The present pharmaceutical composition is especially resistant against flocculation, clumping and/or precipitation at room temperature during prolonged time-periods such as one or more years. | 2010-01-28 |
| 20100022589 | PYRIDINE-3-CARBOXAMIDE COMPOUNDS AND THEIR USE FOR INHIBITING 11-BETA-HYDROXYSTEROID DEHYDROGENASE - Compounds of formula (I): | 2010-01-28 |
| 20100022590 | Novel compounds - The present invention relates to novel isoxazole compounds of formula (I), | 2010-01-28 |
| 20100022591 | PIPERIDINE GPCR AGONISTS - Compounds of formula (I): or pharmaceutically acceptable salts thereof, are GPCR agonists and are useful as for the treatment of obesity and diabetes. | 2010-01-28 |
| 20100022592 | THIAZOLE DERIVATIVES AS MODULATORS OF G PROTEIN-COUPLED RECEPTORS - The invention provides compounds of formula (IA) or (IB) and pharmaceutical compositions thereof, which are useful for modulating G protein-coupled receptor 120 (GPR120), and methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated GPR120. | 2010-01-28 |
| 20100022593 | Process for Producing Anticancer Agent LL-D45042 - The disclosure describes the production of anticancer agent LL-D45042, having the structure: | 2010-01-28 |
| 20100022594 | HETEROCYCLIC SULFONAMIDE INHIBITORS OF BETA AMYLOID PRODUCTION - Compounds of Formula (I), | 2010-01-28 |
| 20100022595 | Benzenesulfonamide Compounds and Their Use as Blockers of Calcium Channels - The invention relates to piperidinyl and hexahydroazepinyl compounds of Formula (I): and pharmaceutically acceptable salts, prodrugs, or solvates thereof, wherein R | 2010-01-28 |
| 20100022596 | EPOTHILONE ANALOGUES - The invention relates to analogues of epothilones, uses and methods of making the same. | 2010-01-28 |
| 20100022597 | 2-ADAMANTYL-BUTYRAMIDE DERIVATIVES AS SELECTIVE 11BETA-HSD1 INHIBITORS - The present invention relates to 2-adamantyl-butyramide derivatives of formula I as selective inhibitors of the enzyme 11-beta-hydroxysteroid dehydrogenase type 1 (11β-HSD-1) and the use of such compounds for the treatment and prevention of metabolic syndrome, diabetes, insulin resistance, obesity, lipid disorders, glaucoma, osteoporosis, cognitive disorders, anxiety, depression, immune disorders, hypertension and other diseases and conditions. | 2010-01-28 |
| 20100022598 | Substituted inmidazoles as bombesin receptor subtype-3 modulators - Certain novel substituted imidazoles are ligands of the human bombesin receptor and, in particular, are selective ligands of the human bombesin receptor subtype-3 (BRS-3). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the modulation of BRS-3, such as obesity, and diabetes. | 2010-01-28 |
| 20100022599 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS - In one aspect, the invention relates to compounds having the formula: | 2010-01-28 |
| 20100022600 | METHODS AND COMPOSITIONS FOR TREATING CENTRAL NERVOUS SYSTEM TUMORS - A method of treating a central nervous system tumor in a subject includes administering a therapeutically effective amount of at least one PPARγ agonist or a derivative thereof to the tumor in the subject. | 2010-01-28 |
| 20100022601 | SULFONAMIDE COMPOUNDS AND THE USE - The sulfoneamide compounds having the following Formula (1), which can be used as an effective component of a CaSR antagonizing agent useful for prophylaxis and/or treatment of bone disorders including osteoporosis and etc., are provided. The compounds have an excellent activity of promoting PTH secretion. In addition, the compounds are useful as an effective component of a medicament for the prophylaxis and/or treatment of bone disorders such as osteoporosis, bone fracture, hypoparathyroidism and the like. | 2010-01-28 |
| 20100022602 | PRE-MIXED, READY-TO-USE IV BOLUS NICARDIPINE COMPOSITIONS AND METHODS OF USE - Provided herein are ready-to-use premixed bolus injection pharmaceutical compositions of nicardipine or a pharmaceutically acceptable salt and methods for use in treating cardiovascular and cerebrovascular conditions. | 2010-01-28 |
| 20100022603 | BICYCLIC ARYL-SULFONIC ACID [1,3,4]-THIADIAZOL-2-YL-AMIDES, PROCESSES FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THEIR USE - The present invention comprises bicyclic aryl-sulfonic acid [1,3,4]-thiadiazol-2-yl-amides, their functional derivatives thereof as well as their physiologically acceptable salts and pharmaceutical compositions thereof that exhibit peroxisome proliferator activated receptor (PPAR) PPARdelta and PPARgamma agonist activity. The structure of the compounds of the invention are defined by Formula I below, | 2010-01-28 |
| 20100022604 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR ALOPECIA - Disclosed is a novel therapeutic agent which is useful for the prevention or treatment of alopecia. Specifically disclosed is a prophylactic or therapeutic agent for alopecia, which comprises 1-[2-((2S)-2-{5-[(3,4-dimethoxyphenoxy)methyl]-1,2,4-oxadiazol-3-yl}pyrrolidin-1-yl)-1,1-difluoro-2-oxoethyl]-3,3,5,5-tetramethylcyclohexanol as an active ingredient. | 2010-01-28 |
| 20100022605 | N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY - Described herein are N-hydroxyamlde antibacterial compounds, methods for making the compounds, pharmaceutical compositions containing the compounds and methods of treating bacterial infections utilizing the compounds and pharmaceutical compositions compound of Formula (I): or a salt, solvate ti hydrate thereof, wherein A is (a) each | 2010-01-28 |
| 20100022606 | Method for reducing odor in personal care products - A personal care composition which contains 25-200 ppm of 2-methyl-4-isothiazolin-3-one and at least one hydroquinone radical scavenger, and a method for reducing odor arising in personal care compositions containing 2-methyl-4-isothiazolin-3-one. | 2010-01-28 |
| 20100022607 | DIAZONAMIDE ANALOGS - Novel diazonamide analogs having anti-mitotic activity, useful for the treatment of cancer and other proliferative disorders are provided. | 2010-01-28 |
| 20100022608 | Non-steroidal anti-inflammatory drugs for cough - The use of a non-steroidal anti-inflammatory drug for the treatment of nonproductive cough caused by viruses or bacteria and a combination of at least one non-steroidal anti-inflammatory drug with at least one antitussive in a formulation to treat coughs. | 2010-01-28 |
| 20100022609 | NOVEL CRYSTALLINE FORMS OF TEMOZOLOMIDE - Disclosed are novel crystalline forms of Temozolomide, methods of preparation thereof, medicaments including the novel crystalline forms of Temozolomide, and uses thereof in the treatment of medical conditions. | 2010-01-28 |
| 20100022610 | New Crystalline Forms - A salt of the compound N-{2-tert-butyl-1-[(4,4-difluorocyclohexyl)methyl]-1H-benzimidazol-5-yl}ethanesulfonamide, which is an ethanesulphonic acid salt, a sulphuric acid salt, an ethane disulphonic acid salt, a hydrochloric acid salt, a hydrobromic acid salt, a phosphoric acid salt, an acetic acid salt, a fumaric acid salt, a maleic acid salt, a tartaric acid salt, a citric acid salt, a methanesulphonic acid salt, or a p-toluenesulphonic acid salt of said compound. | 2010-01-28 |
| 20100022611 | 1,5-Diaryl-Pyrazoles As Cannabinoid Receptor Neutral Antagonists Useful As Therapeutic Agents - The present invention pertains to cannabinoid (CB) receptor neutral antagonists, and especially CB1 neutral antagonists, and including, for example, certain | 2010-01-28 |
| 20100022612 | FUSED HETEROCYCLES - This invention provides fused heterocycles having the formula: | 2010-01-28 |
| 20100022613 | Compounds Having CRTH2 Antagonist Activity - Compounds of general formula (I) | 2010-01-28 |
| 20100022614 | PHARMACEUTICAL COMPOSITION FOR EXTERNAL APPLICATION AND ADHESIVE SKIN PATCH - Disclosed are a pharmaceutical composition for external application, an adhesive skin patch and others which are improved in a drug release property, transdermal absorbability and stability of a pharmacologically active ingredient contained therein and can reduce the aggravation of irritation to the skin. Specifically disclosed is an adhesive skin patch comprising a support and an adhesive layer laminated on the support, wherein the adhesive layer contains a pharmaceutical composition for external application. The pharmaceutical composition for external application comprises a pharmacologically active ingredient, an auxiliary component and a pyrrolidone compound, wherein one of the pharmacologically active ingredient and the auxiliary component has a carboxylate group in the molecule and the other has a hydroxy group in the molecule. Preferably, the adhesive layer further comprises a hydrogenated oil. | 2010-01-28 |
| 20100022615 | ACTIVATED CYTOTOXIC COMPOUNDS FOR ATTACHMENT TO TARGETING MOLECULES FOR THE TREATMENT OF MAMMALIAN DISEASE CONDITIONS - Activated cytotoxic compounds are described for attachment to targeting molecules for the treatment of a mammalian disease condition which comprise, an activator, a spacer linker, a linker (e.g., self-immolative), and a cytotoxic drug selected from the group consisting of AMINO-SUBSTITUTED (E)-2,6-DIALKOXYSTYRYL 4-SUBSTITUTED BENZYLSULFONES, AMINO-AND-HYDROXY SUBSTITUTED STYRYLSULFONANILIDES, and SUBSTITUTED PHENOXY- AND PHENYLTHIO-STYRYLSULFONE DERIVATIVES. Activated cytotoxic compound attached to a targeting molecule are described wherein the targeting molecule is selected from the group consisting essentially of an antibody, a receptor, a ligand, a cytokine, a hormone, and a signal transduction molecule. The invention is further directed to a method of treatment of disease conditions. | 2010-01-28 |
| 20100022616 | 3-(PHENOXYPHENYLMETHYL)PYRROLIDINE COMPOUNDS - In one aspect, the invention relates to compounds of formula I: | 2010-01-28 |
| 20100022617 | COMPOSITIONS AND METHODS TO CONTROL ABNORMAL CELL GROWTH - A class of compounds commonly containing a trialkylammonium group have been synthesized and characterized as anticancer compounds. A representative of this class, N,N-diethyl-N-methyl-2-[(9-oxo-9H-thioxanthen-2-yl)methoxy]ethanaminium iodide (CCDTHT) was shown in various tumor models to decrease tumor volume, enhance the effects of other chemotherapeutic agents including cisplatin, reduce chemotherapy-induced loss of body weight, and increase survival of animals co-treated with toxic amounts of cisplatin. CCDTHT had even greater effects on tumor volume, body weight, and survival when administered to animals together with the human protein placental alkaline phosphatase. These trialkylammonium group-containing compounds and alkaline phosphatases, particularly in combination with each other and other therapies, may be used to treat cancer and other cell proliferative diseases. | 2010-01-28 |
| 20100022618 | Long interfering nucleic acid duplexes targeting multiple RNA targets - Long interfering nucleic acid (iNA) duplexes, which are at least 30 nucleotides in length, which have at least one nick or nucleotide gap in the antisense or the sense strands or in both the sense and antisense strands. These long iNA duplexes do not induce an interferon response when transfected into mammalian cells. The antisense strands can target two separate mRNAs or two segments of one mRNA. | 2010-01-28 |
| 20100022619 | COMPOSITIONS AND THEIR USES DIRECTED TO PTPR ALPHA - Disclosed herein are compounds, compositions and methods for modulating the expression of PTPR.alpha. in a cell, tissue or animal. Also provided are methods of target validation. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders. Also provided are methods for the prevention, amelioration and/or treatment of airway hyperresponsiveness and pulmonary inflammation by administration of antisense compounds targeted to PTPR.alpha. | 2010-01-28 |
| 20100022620 | EPITOPE REDUCTION THERAPY - The present invention provides the use of an inhibitor of glycolipid biosynthesis in the manufacture of a medicament for the treatment of a glycolipid-mediated autoimmune disease. | 2010-01-28 |
| 20100022621 | CONSTRUCTION AND USE OF TRANSFECTION ENHANCER ELEMENTS - Nucleic acids comprising a nucleic acid moiety and two or more transfection enhancer elements (TEE's) according to the general formula (I): Hydrophobic moiety—pH-responsive hydrophilic moiety, wherein said pH sensitive hydrophilic moiety of said TEE is independently a weak acid having a pka of between 4 and 6.5 or is a zwitterionic structure comprising a combination of acidic groups with weak basis having a pKa of between 4.5 and 7. | 2010-01-28 |
| 20100022622 | Dbait and its Standalone Uses Thereof - The invention relates to compositions and methods for interfering with the DNA repair of double strand breaks (DSBs). The invention discloses double-stranded nucleic acid molecules that act as baits and hijack the holocomplex of enzymes responsible of DNA DSB sensing, signaling and/or repair pathways, in particular the non-homologous end joining (NHEJ) pathway of DSB repair. The invention discloses the use of these molecules as a standalone anticancer drug in an efficient amount to be introduced in the tumor cell nuclei in order to trigger their death. | 2010-01-28 |
| 20100022623 | Methods and Compositions for the Treatment of Eye Disorders with Increased Intraocular Pressure - The present invention relates to methods and compositions that decrease intraocular pressure (IOP) of the eye. The compositions of the invention comprise short interfering nucleic acid molecules (siNA) including, but not limited to, siRNA that decrease expression of genes associated with production or drainage of intraocular fluid. The compositions of the invention can be used in the preparation of a medicament for the treatment of an eye conditions displaying increased IOP such as glaucoma, infection, inflammation, uveitis, and diabetic retinopathy. The methods of the invention comprise the administration to a patient in need thereof an effective amount of one or more siNAs of the invention. | 2010-01-28 |
| 20100022624 | Methods of Treating Smooth Muscle Cell Disorders - The present invention provides methods of detecting cells showing smooth muscle differentiation. The present invention further provides methods of detecting tumor cells. The present invention further provides compositions and methods for treating smooth muscle cell disorders. | 2010-01-28 |
| 20100022625 | Structural-based inhibitors of the glutathione binding site in aldose reductase, methods of screening therefor and methods of use - Provided herein is a crystallized ternary structure of aldose reductase (AR) bound to NADPH and γ-glutamyl-S-(1,2-dicarboxyethyl)cysteinylglycine (DCEG). Also provided are specific inhibitors of glutathione-aldehyde binding to aldose reductase which are designed via at least computer modeling of the ternary AR:NADPH:DCEG structure and methods of designing and of screening the inhibitors for inhibition of glutathione-aldehyde binding to aldose reductase. In addition methods of treating a pathophysiological state or symptoms thereof resulting from aldose reductase-mediated signaling in a cytotoxic pathway using a small interfering RNA (siRNA) or the designed inhibitors. | 2010-01-28 |
| 20100022626 | Modulators of cell migration and methods of identifying same - The present invention relates to a method of measuring cell migration, the method comprising (a) contacting a cell with a plurality of polystyrene non-fluorescent beads so as to generate a migratory track; and (b) analyzing at least one morphometric parameter of said migratory track, the morphomotric parameter being indicative of cell migration. The present invention also relates to methods of treating a medical condition associated with cell migration, the method comprising administering to a subject in need thereof a therapeutically effective amount of an agent capable of modulating the activity or expression of genes identified using the above assay, thereby treating the medical condition associated with cell migration. | 2010-01-28 |
| 20100022627 | PREDICTIVE BIOMARKERS FOR CHRONIC ALLOGRAFT NEPHROPATHY - The invention relates to the analysis and identification of genes that are modulated in transplant rejection. This alteration of gene expression provides a molecular signature to accurately detect transplant rejection. | 2010-01-28 |
| 20100022628 | ALTERNATIVE OXIDASE AND USES THEREOF - The invention relates to a method for combating disorders affecting the mitochondrial oxidative phosphorylation system by allotopic expression of the cyanide-insensitive alternative oxidase (AOX) in human cells. The successful expression of AOX in human cells and in | 2010-01-28 |
